News Roche's IgAN hopeful sefaxersen passes phase 3 test Roche has staked a claim to the increasingly crowded IgA nephropathy (IgAN) category with phase 3 data for Ionis-partnered sefaxersen.
News Amgen's Horizon buyout delivers Sjögren's disease win Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.
News Beacon's XLRP gene therapy set for filing after phase 3 win Beacon is preparing to file for approval of its gene therapy for X-linked retinitis pigmentosa, after reporting encouraging phase 3 data.
News FDA unveils framework for its expedited IND pilot The FDA has published the design of its expedited Investigational New Drug pilot, part of a plan to restore US competitiveness in clinical research.
News WCLC: Lung cancer news from BioNTech, Akeso, and Roche As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.
News AZ's Etcamah falls short in first-line breast cancer trial A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.